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In manufacturing businesses and business schools through-
out America, one of the prevailing tenets of management is
that variance from a predefined norm is the source of
avoidable costs, and its elimination is one of the keys to
efficient operations. A widget that is larger or smaller than
a defined standard is a source of consternation that must be
eliminated. Leading businesses pride themselves in their
fanatical devotion to the prevention and elimination of
variance.
ANGIOPLASTIES ARE NOT WIDGETS
The same principles are now being examined and applied by
those who manage health care provider and payer organi-
zations. It has been well recognized that substantial vari-
ability exists in practice patterns both geographically and
between individual practitioners and that this variability can
translate into differences in cost (1,2). The elimination of
variance is at the heart of utilization review as a manage-
ment tool. Its goals are to identify and rectify practices that
either exceed norms or go beyond the bounds of clinical
guidelines. What has sometimes escaped the attention of
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those who would stamp out variance in the practice of
medicine is that the innate biologic variability among
patients and the human dimensions of providing health care
do not naturally lend themselves to efforts to achieve
uniformity, much as in the manufacture of widgets.
The use of physician economic profiling has been exam-
ined in various clinical settings (3), and it comes as no
surprise that these management practices have now reached
into the cardiac catheterization laboratory. The conduct of
percutaneous coronary interventions is capital-intensive. It
involves expensive consumable items and personnel time. It
is also readily apparent that much of this consumption
comes in variable quantities at the hands of different
interventional cardiologists. One interventionalist can, in a
brief interval, directly consume large amounts of financial
resources. Thus, it is natural that managers are interested in
tracking and controlling behaviors in the catheterization
laboratory.
Confronted with raw summary data of any aspect of
clinical performance, be it clinical outcomes or economic
costs, physicians are naturally and sensibly inclined to
invoke the notion that their patients are more complicated
than the patients of other physicians as an explanatory
factor. What has been heretofore completely lacking in
cost-accounting efforts in the catheterization laboratory is
adequate control of case-mix complexity. Merely to enu-
merate the costs of cases or physicians, of which many
hospital cost-accounting systems are capable, misses a basic
point: complicated cases are more expensive (3–5). To be
sure, there are commercially available cost-accounting sys-
tems that purport to be able to control for case-mix severity.
With a single click of the mouse, a well-meaning adminis-
trator has the capability, ostensibly, to adjust physicians’ cost
profiles for their case-mix severity. These systems’ clinical
models, however, are not transparent. Neither the elements
that are entered into the case-mix adjustments nor the
validation data that support these models are readily avail-
able to would-be users; thus, from a physician’s perspective,
they lack all credibility.
Upon this background, as presented in this issue of the
Journal, Cowper et al. (6) at Duke University take the field
a stride forward by showing us that appropriate profiling
efforts must be based both on accurate cost-accounting and
on appropriate clinical data. Over a two-year period, these
investigators collected both economic and clinical data on a
group of interventionalists. Their conclusion, which appeals
to one’s common sense, is that adjusting for case-mix
severity is important in correctly interpreting cost data.
After adjustment, several operators who would initially have
been identified as outliers no longer differed from the norm.
Other operators, who in the unadjusted data-set looked like
everyone else, subsequently emerged as outliers once the
appropriate adjustments were performed.
STRENGTHS AND LIMITATIONS OF
PROFILING AND OF THE CURRENT MODEL
The research methodologies of Cowper et al. (6) are sound.
Without belaboring the minutia of cost-accounting and
statistics, it will suffice to say that the cost data was
appropriately tabulated and analyzed from clinical, mana-
gerial and statistical viewpoints.
The clinical data used for risk adjustment are fairly
complete, though some potentially important elements may
have been excluded. Angiographers will quickly recognize
that lesion type can be an important driver of equipment
utilization in the catheterization laboratory. Bifurcation
lesions, for example, can be expected to be more expensive
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than simpler lesions. Though the issue of potentially incom-
plete or imperfect clinical modeling is a substantive one, we
will not quibble about this. It is not likely that a more
perfect model would change the overall results or conclu-
sions reached by Cowper et al. (6).
The practice of the cardiologists at the institution studied
was similar to national norms for such items as stents, other
interventional modalities and adjunctive glycoprotein IIb-
IIIa inhibitors. Thus, the cost dimensions of the Duke
interventionalists may be expected to be representative of
national patterns. Nevertheless, the cost structure of any one
institution may not be applicable universally as different
hospitals have different pricing and different fixed costs with
which to deal.
One inherent limitation of all profiling tools is the issue
of “temporal stability.” This is a relevant issue both for an
individual operator’s performance and for the clinical model
and the cost-accounting. To the former issue, an individual
outlier can legitimately claim that his (or her) performance
during a given time period is not representative as there may
have been extraordinary cases or circumstances. Thus, to
credibly label someone as a true outlier will take several
periods of observations and a substantial numbers of cases.
The reality is that it may take years of data before one can
reach a firm conclusion that an individual is a true outlier.
Like any measured phenomenon, catheterization-laboratory
costs will likely demonstrate a regression toward the mean
over time. Thus, even in the absence of any intervention to
improve performance, an outlier during the time period
studied by Cowper et al. (6) is likely to be within the normal
range for the next time period and will expect a laudatory
note from his or her administrator on the outlier’s improved
performance.
Equally important is the idea that time marches on for
the risk-adjustment models. As older technologies become
less expensive in a competitive marketplace, and as newer,
costly ones emerge to address specific clinical and angio-
graphic problems, the predictors of what drives costs will
change. Thus, the risk-adjustment models need continuous
revalidation or recalibration. This will require much time
and effort.
Overall, the present study (6) provides strong evidence to
support risk adjustment for economic profiling, and physi-
cians are within their rights in demanding it of any
cost-accounting system that may be imposed upon them.
HOW CAN THIS RISK-ADJUSTED
ECONOMIC PROFILING BE USED?
For whom is this risk-adjustment tool intended? Payers
have largely insulated themselves from the parochial issues
of catheterization-laboratory costs by erecting diagnosis-
related group (DRG)-based or capitated-payment systems.
It is the minority of cardiology patients whose insurers
reimburse hospitals on a per item basis. The worry of how
efficiently the hospital runs is not the concern of Medicare
or health maintenance organizations (HMOs).
Largely, the issue of containing costs at the level ad-
dressed by Cowper et al. (6) is of interest to hospitals.
Self-contained systems, such as staff-model HMOs, that
also own their hospitals, or the Veterans Affairs (VA)
system, are uniquely focused on operational cost-
containment, but in the aggregate these entities account for
a minority of American medicine. For most hospitals, the
revenues from an episode of care for a cardiovascular patient
is fixed either by DRGs or capitation. Thus, cost contain-
ment becomes a matter of survival.
If it is the hospitals that have the greatest stake in
controlling these sorts of operational costs, then it is the
nature of their relationship to their physicians that will
determine how they can put physician economic profiling to
use. Hospitals that are in competition with nearby institu-
tions to attract and retain private practice physicians and
market share are not likely to strongly pressure their
physicians on cost containment. Entities with greater con-
trol of their physicians, such as academic institutions with
employee-physicians or those unusual institutions with
geographic monopolies who do not need to worry about the
loyalties of their catheterizing physicians, are positioned to
more intensively monitor and manage their doctors.
Even a hospital with little leverage over its physician staff
could find utility in a profiling tool. Conversely, even an
institution that has potentially tight control of its physician
staff may find its use of profiling limited.
Perhaps the most effective application of profiling is in
physician-feedback efforts (7). Even in the absence of any
administrative clout, these have been effective in reducing
costs (7). In business schools, this is known as the “Haw-
thorne effect.” Shine a light on an issue and it will naturally
improve. That which gets measured gets done. But whether
efforts to control costs through the use of such profiling
tools can go beyond physician feedback is highly dubious. It
may, for example, be possible to ask an efficient colleague to
coach an inefficient colleague, but one must account for the
costs of the physician’s time in such an effort. More
draconian initiatives, such as restricting physicians’ prac-
tices, are unlikely to succeed and will be far more costly in
terms of intangibles such as loss of goodwill and possible
legal redress on the part of the excluded physician.
In the final analysis, the usefulness of profiling may be
very limited in terms of what is at stake. If the goal, like in
manufacturing, is to reduce costs by reducing variance, the
data of Cowper et al. (6) are illustrative of the limitations.
Of the 50 operators, only 3 were outliers. We can estimate
that their variance from the norm accounted for approxi-
mately $180,000 of the total variable catheterization-
laboratory costs for the institution during the 18-month
study period, or 1.5% of the catheterization-laboratory
budget of $11.8 million. Examining the variability in total
hospital costs, none of the providers were outliers, and thus
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there is no cost-savings opportunity in striving to eliminate
variance.
Alternatively, if the goal is to prompt all the operators to
become as efficient as the very efficient outliers, this may be
an elusive goal, akin to goading the batters of a major-league
baseball team to all hit 70 home runs like Mark McGwire.
It may be that the two low-cost outliers are truly exceptional
operators and all of the other highly trained, highly profes-
sional interventionalists will never equal their performance.
In conducting a program of physician profiling, the costs
of appropriate risk adjustment and feedback must be bal-
anced against the catheterization-laboratory costs to be
saved. As Cowper et al. (6) underscore, the necessary clinical
data to conduct appropriate case-mix adjustment does not
exist in administrative data-sets. Someone has to gather,
enter, and merge the clinical data with the administrative
data. As more catheterization laboratories deploy automated
systems for collecting clinical data (in particular to partici-
pate in regional or national databases) the merging of
clinical and administrative data is simplified. But this raises
issues about the accuracy of such efforts. For many clinical
databases, the operators provide most of the key baseline
information. If they perceive that this information is sub-
sequently used to profile them, be it on clinical outcomes or
economic dimensions, they will quickly learn to game the
system by upgrading patients’ clinical or angiographic char-
acteristics. This sort of “creep” in risk-factor reporting has
been well recognized (8).
Other unintended consequences of profiling must also be
considered. There are legitimate concerns that clinical-
outcomes reporting can lead to refusal of operators to
undertake complex cases (9). This could also apply to
economic profiling.
The opportunities to contain costs in the catheterization
laboratory are greater via approaches other than physician
profiling. In contrast to profiling efforts, if the administra-
tors could reduce costs by negotiating better contracts with
vendors, the savings would apply to all operators’ work, not
just the expensive outliers. In the present study, a 10%
reduction in catheterization-laboratory hardware would
have translated into a savings of $1.2 million, which dwarfs
the $180,000 savings from “correcting” the outliers. The
investigators admit, for example, that future decisions such
as which glycoprotein IIb-IIIa inhibitor to use could have
substantial impact on their costs. Also, concentrating their
hardware inventory to one or several preferred vendors could
increase the institution’s clout in purchasing contracts.
Thus, seeking (and winning) the cooperation of the inter-
ventionalists in accepting a smaller inventory is likely to
result in far greater rewards for the institution than are
intensive efforts at physician profiling.
The goal the hospitals seek is cost-savings. Hospitals will
not attain that goal (and will risk antagonizing their
interventionalists) through profiling efforts, even efforts that
are conducted with credibility and care such as the present
Duke University effort. There are greater opportunities for
the hospital via other cost-containment efforts in the cath-
eterization laboratory, efforts achieved only through coop-
eration with the operating cardiologists.
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